Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,322.36 +19.09 (+0.36%) Dow
39,987.77 -15.82 (-0.04%) Nasdaq
16,820.46 +134.49 (+0.81%) Bitcoin USD
68,424.21 +1,773.29 (+2.66%) CMC Crypto 200
1,388.83 +34.42 (+2.54%)
Senseonics Holdings, Inc. (SENS)
| Previous close | 0.4851 |
| Open | 0.4852 |
| Bid | 0.4650 x 900 |
| Ask | 0.4653 x 900 |
| Day's range | 0.4628 - 0.4901 |
| 52-week range | 0.3840 - 1.0500 |
| Volume | |
| Avg. volume | 2,441,685 |
| Market cap | 247.977M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results
GERMANTOWN, Md., May 13, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2024.
- Business Wire
Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
GERMANTOWN, Md. & CHESTERFIELD, Mo., May 13, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM) systems for people with diabetes, in partnership with our global commercial partner, Ascensia Diabetes Care, and St. Louis-based Mercy, a leading health care system and accountable care organization, today announced a first-of-its-kind relationship in a diabetes popu
- Business Wire
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
GERMANTOWN, Md., May 09, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a strategic partnership with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, in the development of its
